Deep Tech Startups

Cambridge Nucleomics develops a single-molecule RNA counting "nanoarray" assay based on solid-state nanopore and DNA nanotechnology for diagnostic testing. The company applies its technology to RNA biology and microbiology-based diagnostics.

1 investor

The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.

1 investor

Cambridge Heavy develops compact inertial confinement fusion machines designed to produce tritium, a critical fuel required to power next-generation fusion reactors. The company targets the global fusion industry with benchtop-scale systems that address the severe shortage of tritium supply.

1 investor

Cambridge Orthopaedic Labs develops non-invasive trauma fixation technologies for orthopaedic trauma surgery, including a platform for non-surgical management of fractures used by surgeons and healthcare providers. The company conducts research in Cambridge, UK and runs headquarters and sales operations in Pennsylvania, US.

1 investor

Canatu develops carbon nanotubes and related carbon nanomaterials for use in industrial products, with a current focus on the semiconductor and automotive industries. The company designs advanced CNT materials intended to enable new product capabilities for manufacturers.

1 investor

Cantoni Therapeutics develops small molecule inhibitors targeting nicotinamide N-methyltransferase (NNMT) for the treatment of metabolic and oncology diseases. The company is a discovery and preclinical stage biotech enterprise based in the Netherlands.

1 investor

Canvas develops secure, scalable software and data integration solutions for mission-critical military and government applications, including full-stack development, real-time telemetry processing, optical imagery analytics, and training systems. The company serves defense and government customers requiring reliable systems for testing, training, and operational environments.

1 investor

Cape Haven Bio is a venture creation firm focused on translating early-stage academic discoveries into commercially viable biotech companies developing therapeutics. The firm provides strategic planning, lab infrastructure, seed capital, and consulting resources to support the progression from research to investable business.

1 investor

Capitainer develops microfluidic microsampling devices that let patients self-collect exact volumes of whole blood, plasma, and urine at home and mail the samples to a laboratory for analysis. Its products serve healthcare organizations for clinical diagnostics and research.

1 investor

Capital Factory is a venture firm based in Texas that invests in early-stage companies building deep and frontier technologies including robotics, aerospace, healthcare, and national security. The firm operates through two vehicles: the Texas Fund for first-check investments and All Access, a network connecting portfolio companies with introductions, customers, and capital.

1 investor

Capital 2B is a venture capital firm that invests in deep-tech and IP-led startups from pre-seed to Series A, writing first cheques of $200k–$3M, often as the first institutional investor. It focuses on companies at the intersection of computation, programmable biology, and advanced materials.

1 investor

Capoom provides 3D modeling, 3D scanning, and synthetic data solutions for AI training, simulations, and digital twins across various industries.

1 investor

Capra Robotics develops multifunctional autonomous mobile robot platforms for inspection, logistics, maintenance, and last-mile delivery. The company prioritizes product safety, sustainable materials, and responsible operations to support businesses in automating manual tasks while minimizing environmental and social impact.

1 investor

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.

1 investor

CapsulateBio develops ingestible robotic pills for oral delivery of biologic drugs, using platforms that deposit liquid or solid biologics directly into the wall of the small intestine or stomach to achieve injectable-like bioavailability. Spun out of the Langer and Traverso Labs at MIT, the company targets pharmaceutical drug delivery for biologics that have traditionally required injection.

1 investor

Capuchin is an AI-powered enterprise search and knowledge management platform designed for engineering organizations that work with hardware, antennas, RF systems, optics, robotics, and similar technical products. The system operates entirely on-premise, indexing product data from PDM/PLM systems, ERPs, and collaboration tools while maintaining ITAR and CMMC compliance for defense and government-facing engineering teams.

1 investor

Carbo Energy builds hybrid non-aqueous redox flow batteries for grid-scale energy storage, designed to complement renewable energy sources with a 40-year lifespan, zero fire risk, and degradation of 0.2% annually. The company serves utilities, datacenters, mining operations, and renewable energy farms across multiple markets including energy trading, backup power, and off-grid operations.

1 investor

Carbon Asset Solutions uses Mobile Inelastic Neutron Scattering (INS) technology to provide land managers with real-time, in-situ soil measurement, analysis and mapping of characteristics such as carbon, moisture and minerals. It also runs soil carbon credit programs connecting suppliers who sequester carbon with buyers seeking verified soil carbon projects.

1 investor

Carbon Clean Energy develops carbon conversion technology that transforms CO2 into chemicals, materials, and fuels using an artificial photosynthesis approach powered by renewable energy. The company serves industrial manufacturers and enterprises seeking decarbonization solutions and carbon-neutral product alternatives.

1 investor

Carbonext produces high-quality 3D graphene using a scalable chemical process that substitutes graphite with biomass and industrial waste materials. The company targets commercial applications by reducing graphene production costs and enabling bulk supply at scale.

1 investor

Carbon Revolution manufactures one-piece carbon fibre wheels for high-performance and luxury vehicles, supplying major automotive OEMs including Ferrari, Ford, General Motors, Jaguar Land Rover, and Lamborghini. The company also offers carbon fibre wheels directly to consumers through its CR-9 product line.

1 investor

Carocell Bio develops peptide-based anti-inflammatory therapeutics, including its lead peptide JEL0305, that inhibit the intracellular MAPK (p38) inflammatory pathway and are combined with a nanoparticle delivery technology for topical application to the skin. It targets inflammatory conditions such as eczema (atopic dermatitis) and inflammation-related skin ageing.

1 investor

CarpeCarbon develops Direct Air Capture (DAC) technology to capture CO2 directly from ambient air and store it permanently, using proprietary processes designed for low electrical energy consumption (under 300 kWh/tCO₂). It is presented as the first Italian company working on this carbon removal approach.

1 investor

Carpo Novum manufactures biodegradable anastomotic ring systems for surgical bowel resection and reconnection procedures in colorectal surgery. The products are designed to simplify minimally invasive intestinal anastomosis while automatically evacuating from the body within 8-12 days.

1 investor